Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting

IRVING, Texas, March 11, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading cancer centers, will collectively present five studies at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting in San Antonio, Texas to be held March 21-26, 2026.

Caris' robust multimodal database, comprised of Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), IHC and real-world clinical data, was used to generate the results being presented. The studies, including one oral presentation and four posters, will cover soft tissue and bone sarcomas, melanoma and gastrointestinal stromal tumors. These posters and presentation represent a collaborative effort between Caris and over 20 cancer centers and institutions across the United States and Europe.

"USCAP offers a great opportunity for pathologists to showcase the latest advances and publications in our industry. We're presenting across multiple topics, incorporating real‑world outcomes and uncovering insights that bring us closer to truly personalized treatment pathways," said Matthew Oberley, MD, PhD, SVP, Chief Clinical Officer and Pathologist-in-Chief at Caris.    

Oral Presentation:

• BCORL1::CREBBP Fusions Characterize an Aggressive Frequently Ossifying Bone and Soft Tissue Sarcoma with Predilection for the Clavicular Bone. Oral #808
  • Platform - Tuesday PM - Bone and Soft Tissue Pathology. March 24, 2026. Presentation Time:  2:00 PM – 2:15 PM CDT

Posters Include:

• Landscape and Molecular/Clinical Correlates of Pathogenic Gene Fusions in Melanoma: A Comprehensive Molecular Profiling Study. Poster #48
  • Poster II - Monday PM - Dermatopathology. March 23, 2026. Time:  1:00 PM – 4:30 PM CDT
• Comprehensive Analysis of Adult NTRK-Rearranged Sarcomas: Clinical, Pathologic, and Genomic Correlates. Poster #69
  • Poster II - Monday PM - Bone and Soft Tissue Pathology. March 23, 2026. Time:  1:00 PM – 4:30 PM CDT
• Secondary Genetic Alterations in Extraskeletal Myxoid Chondrosarcoma: Beyond NR4A3. Poster #70
  • Poster II - Monday PM - Bone and Soft Tissue Pathology. March 23, 2026. Time:  1:00 PM – 4:30 PM CDT
• Interplay of Programmed Death-Ligand 1 (PD-L1) Expression in Gastrointestinal Stromal Tumor (GIST): Correlation with Clinicopathologic Features, Comprehensive Genomic Profile, and Disease Outcome. Poster #63
  • Poster IV – Tuesday PM – Bone and Soft Tissue Pathology. March 24, 2026. Time:  1:00 PM – 4:30 PM CDT

Research highlights will be available onsite at Caris' booth #512. The full abstracts will be available on the Caris website following the presentations.

About Caris Life Sciences 

Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.   

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.   

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.  

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.

Caris Life Sciences Media:

Corporate Communications 

[email protected] 

214.294.5606  

SOURCE Caris Life Sciences